Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01019928
Other study ID # D9127C00002
Secondary ID 2008-007420-26
Status Completed
Phase Phase 2
First received November 20, 2009
Last updated October 10, 2012
Start date November 2009
Est. completion date January 2011

Study information

Verified date October 2012
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines AgencySweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date January 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Provision of signed informed consent form

- BMI 18.5-35.0, inclusive

- Continuous PPI treatment for GERD during the last 4 weeks

Exclusion Criteria:

- Patients that have not experienced any GERD symptoms improvement at all after PPI treatment

- Unstable or clinically significant disorders including cardiovascular, respiratory, renal, hepatic, metabolic, psychiatric, other gastrointestinal and esophageal disorders besides GERD

- Prior surgery of the upper GI tract

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
AZD1386
95 mg, oral solution, single dose
Placebo to AZD1386
Placebo, oral solution, single dose

Locations

Country Name City State
Denmark Research Site Århus C
Sweden Research Site Goteborg Vastra Gotaland

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

Denmark,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 1.5 Hours Post-Dose. A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Heat stimuli were applied by recirculation of heated water in the bag. Prior to recirculation the bag is filled with 7mL to ensure adequate mucosal contact. Water was heated up to a maximum of 63° C and the stimulation was continued until VAS 7 was reached.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
1.5 hours post dose No
Secondary Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 0.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Heat stimuli were applied by recirculation of heated water in the bag. Prior to recirculation the bag is filled with 7mL to ensure adequate mucosal contact. Water was heated up to a maximum of 63° C and the stimulation was continued until VAS 7 was reached.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
0.5 hours post dose No
Secondary Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 2.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Heat stimuli were applied by recirculation of heated water in the bag. Prior to recirculation the bag is filled with 7mL to ensure adequate mucosal contact. Water was heated up to a maximum of 63° C and the stimulation was continued until VAS 7 was reached.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
2.5 hours post dose No
Secondary Volume at Visual Analogue Scale 7 (VAS7) During Mechanical Stimulation at 0.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Volume change in the bag was recorded continuously at each level of the visual analogue scale (VAS) and up to VAS7 (Volume at Visual Analogue Scale 7).
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
0.5 hours post dose No
Secondary Volume at Visual Analogue Scale 7 (VAS7) During Mechanical Stimulation at 1.5 Hours Post-Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Volume change in the bag was recorded continuously at each level of the visual analogue scale (VAS) and up to VAS7 (Volume at Visual Analogue Scale 7).
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
1.5 hours post dose No
Secondary Volume at Visual Analogue Scale 7 (VAS7) During Mechanical Stimulation at 2.5 Hours Post-Dose. A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES). Volume change in the bag was recorded continuously at each level of the visual analogue scale (VAS) and up to VAS7 (Volume at Visual Analogue Scale 7).
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
2.5 hours post dose No
Secondary Current at Visual Analogue Scale 7 (VAS7) During Electrical Stimulation 0.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES) and stimulations were performed at approximately 8 cm above the LES. The intensity of the stimuli is increased steadily in steps of 0.5 to 1 mA and the intensity corresponding to the VAS levels 1, 3, 5 and 7 were recorded.
The current will be increased until the patient report moderate pain (VAS 7) or max 80 mA.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
0.5 hours post dose No
Secondary Current at Visual Analogue Scale 7 (VAS7) During Electrical Stimulation at 1.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES) and stimulations were performed at approximately 8 cm above the LES. The intensity of the stimuli is increased steadily in steps of 0.5 to 1 mA and the intensity corresponding to the VAS levels 1, 3, 5 and 7 were recorded.
The current will be increased until the patient report moderate pain (VAS 7) or max 80 mA.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
1.5 hours post dose No
Secondary Current at Visual Analogue Scale 7 (VAS7) During Electrical Stimulation at 2.5 Hours Post Dose A probe (bag) was inserted 7cm above the lower esophageal sphincter (LES) and stimulations were performed at approximately 8 cm above the LES. The intensity of the stimuli is increased steadily in steps of 0.5 to 1 mA and the intensity corresponding to the VAS levels 1, 3, 5 and 7 were recorded.
The current will be increased until the patient report moderate pain (VAS 7) or max 80 mA.
The intensities of the non-painful sensations were scored with the following descriptors added to facilitate the scoring:
= vague perception of mild sensation
= definite perception of mild sensation
= vague perception of moderate sensation
= definite perception of moderate sensation
For painful sensations the patients will use the scale from 5-10 anchored at:
= pain detection
= slight pain
= moderate pain
= medium pain intensity
= intense pain
= unbearable pain
2.5 hours post dose No
Secondary AUCt Area under the plasma concentration curve from time zero to the last quantifiable concentration 0 to 4 hours post dose No
Secondary Cmax Maximum plasma concentration 0 to 4 hours post dose No
Secondary Tmax Time of maximum plasma concentration 0 to 4 hours post dose No
Secondary SBP Supine Systolic Blood Pressure at 1.5 hours post dose 1.5 hours post dose Yes
Secondary DBP Supine Diastolic Blood Pressure at 1.5 hours post dose 1.5 hours post dose Yes
Secondary Pulse Supine Pulse at 1.5 hours post dose 1.5 hours post dose Yes
Secondary QTcF QT interval corrected for heart rate using Fredericia formula(QTcF) at 1.5 hours post dose 1.5 hours post dose Yes
Secondary Body Temperature Oral Body Temperature at 1.5 hours post dose 1.5 hours post dose Yes
Secondary Clinically Relevant Change of Laboratory Variables Number of participants with clinically relevant change of laboratory variables(clinical chemistry, haematology and urinalysis parameters) Pre-entry to follow-up Yes